A Clinical Trial of CNCT19 Cells in the Treatment of CD19 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia

NCT04230473 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

10

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed or Refractory Acute Lymphoblastic Leukemia

Interventions

BIOLOGICAL: single dose of CNCT19

Sponsor

Juventas Cell Therapy Ltd.